This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Javelin Pharmaceuticals, Inc. Reports First Quarter 2010 Results

Javelin Pharmaceuticals, Inc. (NYSE Amex: JAV - News), a leading developer of novel acute care pain products, today reported its unaudited financial results for the first quarter ended March 31, 2010.

Highlights for the three months ended March 31, 2010:
  • Ended the first quarter with approximately $1.1 million in cash and cash equivalents
  • Net loss decreased to approximately $6.3 million, or $0.10 per share, in the first quarter of 2010 from approximately $14.8 million, or $0.24 per share, in the first quarter of 2009
  • In February 2010, Javelin received an FDA PDUFA date of October 3, 2010 for Dylojectâ„¢
  • On April 19, 2010, Javelin announced that it had entered into a Definitive Merger Agreement with Hospira, Inc. pursuant to which Hospira launched an all cash tender offer of $2.20 per share. The transaction is scheduled to close during the second quarter of 2010.

Financial Performance

For the three months ended March 31, 2010, we recorded $0.3 million in amortization of partner milestone payments compared to $0.2 million for the similar period a year ago. For the three months ended March 31, 2009, partner revenue also included approximately $1.7 million in product sale to Therabel.

For the three months ended March 31, 2010, our cost of revenue was approximately $0.1 million, compared to $1.9 million for the same period a year ago. Our cost of revenue for the period ended March 31, 2010 is primarily attributable to our portion of royalties that were payable to third parties for sales recorded by Therabel.

Research and development expenses for the three months ended March 31, 2010, were $3.9 million compared to $11.8 million for the same period in 2009. Total research and development expense for the quarter decreased to $6.5 million from $16.9 million for the similar period a year ago, primarily attributable to reductions in clinical trial expenses for Dyloject and Ereska.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
AAPL $123.04 -0.28%
FB $96.21 0.97%
GOOG $629.69 0.27%
TSLA $266.02 0.45%
YHOO $37.65 -0.19%

Markets

Chart of I:DJI
DOW 17,760.41 +130.14 0.74%
S&P 500 2,107.35 +14.10 0.67%
NASDAQ 5,109.3650 +20.1590 0.40%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs